Log in

NASDAQ:VRCA - Verrica Pharmaceuticals Stock Price, Forecast & News

$9.68
+0.66 (+7.32 %)
(As of 04/3/2020 06:00 AM ET)
Today's Range
$9.02
Now: $9.68
$10.20
50-Day Range
$7.14
MA: $11.59
$14.93
52-Week Range
$6.79
Now: $9.68
$18.67
Volume46,962 shs
Average Volume69,022 shs
Market Capitalization$249.61 million
P/E RatioN/A
Dividend YieldN/A
Beta2.86
Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company was founded in 2013 and is headquartered in West Chester, Pennsylvania.
Read More
Verrica Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRCA
CUSIPN/A
CIKN/A
Phone484-453-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.52 per share

Profitability

Net Income$-28,210,000.00

Miscellaneous

Employees16
Market Cap$249.61 million
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable

Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.


Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

How has Verrica Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VRCA shares have decreased by 8.0% and is now trading at $9.68. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Verrica Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Verrica Pharmaceuticals.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Verrica Pharmaceuticals.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) issued its earnings results on Friday, March, 13th. The company reported ($0.31) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.01. View Verrica Pharmaceuticals' earnings history.

What price target have analysts set for VRCA?

2 brokers have issued 12 month price objectives for Verrica Pharmaceuticals' shares. Their forecasts range from $20.00 to $24.00. On average, they expect Verrica Pharmaceuticals' share price to reach $22.00 in the next twelve months. This suggests a possible upside of 127.3% from the stock's current price. View analysts' price targets for Verrica Pharmaceuticals.

Has Verrica Pharmaceuticals been receiving favorable news coverage?

Media stories about VRCA stock have trended very negative on Friday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Verrica Pharmaceuticals earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutVerrica Pharmaceuticals.

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 730,800 shares, an increase of 23.0% from the February 13th total of 594,100 shares. Based on an average trading volume of 66,300 shares, the days-to-cover ratio is presently 11.0 days. Approximately 5.7% of the company's stock are short sold. View Verrica Pharmaceuticals' Current Options Chain.

Who are some of Verrica Pharmaceuticals' key competitors?

What other stocks do shareholders of Verrica Pharmaceuticals own?

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:
  • Mr. Ted White, Pres, CEO & Director (Age 54)
  • Mr. Chris Degnan, Chief Financial Officer (Age 39)
  • Mr. Joe Bonaccorso, Chief Commercial Officer (Age 55)
  • Dr. Patrick Burnett M.D., Ph.D., Chief Medical Officer (Age 47)
  • Christopher G. Hayes, Sec.

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $9.68.

How big of a company is Verrica Pharmaceuticals?

Verrica Pharmaceuticals has a market capitalization of $249.61 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe. View additional information about Verrica Pharmaceuticals.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is http://www.verrica.com/.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]


MarketBeat Community Rating for Verrica Pharmaceuticals (NASDAQ VRCA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  244
MarketBeat's community ratings are surveys of what our community members think about Verrica Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel